Gene variants and how type 2 diabetes patients respond to exenatide
Studies whether gene variants affect how adults with type 2 diabetes respond to exenatide.
Plain-language title generated from the registry record
Registry title: Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
Key facts
- Where
- Xuzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 70 years old?
Source: NCT06256419, who can take part
Where in China
- China, Jiangsu, Department of EndocrinologyXuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Hospital of Xuzhou Medical University
- Trial code
- NCT06256419
- Record updated
- 18 September 2025
- Original description
This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can predict the efficacy of GLP-1 RA, and to evaluate the weight of these variables on the efficacy.Read full original descriptionShow less
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can predict the efficacy of GLP-1 RA, and to evaluate the weight of these variables on the efficacy.
Inclusion: a diagnosis of T2DM; a body mass index (BMI) of 20-35 kg/m2; an HbA1c of 7.0%-12%, an age of 25-70 years; required data available at baseline and 6 months after GLP-1RA therapy.
Exclusion: patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months; those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy; Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis.